Immunotherapy drug may save eyes from aggressive skin cancer
NCT ID NCT06580054
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This study tests whether the immunotherapy drug pembrolizumab can shrink or control advanced or recurrent skin cancer near the eye. About 22 adults with this condition will receive the drug. The goal is to see if the cancer responds and if the eye can be saved from surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
- Cancer drug trial halted after just one patient
- Remote hearing tests could save cancer Patients' hearing
- Could an antidepressant ease cancer treatment pain? new study investigates
- New study aims to make allergy testing safer for cancer patients on biologics
- New proton beam therapy aims to zap head and neck cancer with fewer side effects